A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS ® 250/50 Inhalation Powder/GSK in Healthy Volunteers
Conditions: Bioequivalence; Asthma Interventions: Drug: Test; Drug: Reference Sponsors: Respirent Pharmaceuticals Co Ltd.; BECRO Ltd. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2021 Category: Research Source Type: clinical trials
A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS ® 250/50 Inhalation Powder/GSK in Healthy Volunteers
Conditions: Bioequivalence; Asthma Interventions: Drug: Test; Drug: Reference Sponsors: Respirent Pharmaceuticals Co Ltd.; Becro Ltd. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2021 Category: Research Source Type: clinical trials
A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS ® 250/50 Inhalation Powder/GSK in Healthy Volunteers
Conditions: Bioequivalence; Asthma Interventions: Drug: Test; Drug: Reference Sponsors: Respirent Pharmaceuticals Co Ltd.; BECRO Ltd. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2021 Category: Research Source Type: clinical trials
Ellodi Pharmaceuticals Announces Fast Track Designation Granted by the FDA to APT-1011 for the Treatment of Eosinophilic Esophagitis (EoE)
Lawrenceville, N.J.– February 8, 2021 – Ellodi Pharmaceuticals, a gastroenterology-focused specialty pharmaceutical company, today announced that APT-1011 (fluticasone propionate oral disintegrating tablet) has been granted Fast... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 8, 2021 Category: Pharmaceuticals Source Type: clinical trials
A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS ® 100mcg/Blister Oral Inhalation Powder/GSK in Patients With Asthma
Condition: Asthma Interventions: Drug: Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmaceuticals; Drug: FLOVENT DISKUS® 100 mcg/blister oral inhalation powder/GSK; Drug: Placebo Sponsors: Respirent Pharmaceuticals Co Ltd.; BECRO Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 14, 2020 Category: Research Source Type: clinical trials
